Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model

International Journal of Oncology

Volumn 44, Issue 1, 2014, Pages 147-152

  Jankun, Jerzy ^a   Keck, Rick W ^a   Selman, Steven H ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Bladder cancer; Epigallocatechin 3 gallate; Membrane metalloproteinase; Mitomycin C; Urokinase

Indexed keywords

EPIGALLOCATECHIN GALLATE; GELATINASE B; MITOMYCIN; POLYPHENON E; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BLADDER INJURY; BLADDER IRRIGATION; BLADDER TUMOR; CANCER STAGING; CANCER TRANSPLANTATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; EXPERIMENTAL RAT; FEMALE; IN VIVO STUDY; MOLECULAR MODEL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; RAT; THERAPY EFFECT; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH;

ANIMALS; CATECHIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MITOMYCIN; NEOPLASMS, EXPERIMENTAL; RATS; URINARY BLADDER NEOPLASMS;

EID: 84891936039     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2174     Document Type: Article

References (56)

1. Kemberling JK, Hampton JA, Keck RW, Gomez MA and Selman SH: Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. J Urol 170: 773-776, 2003.
2. Weldon TE and Soloway MS: Susceptibility of urothelium to neoplastic cellular implantation. Urology 5: 824-827, 1975.
3. Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 25: 219-278, 2001.
4. Resnick MJ, Bassett JC and Clark PE: Management of superficial and muscle-invasive urothelial cancers of the bladder. Curr Opin Oncol 25: 281-288, 2013.
5. Ho YC, Yang SF, Peng CY, Chou MY and Chang YC: Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metallo-proteinases and urokinase-plasminogen activator. J Oral Pathol Med 36: 588-593, 2007.
6. Rogers AE, Hafer LJ, Iskander YS and Yang S: Black tea and mammary gland carcinogenesis by 7,12-dimethylbenz[a]anthracene in rats fed control or high fat diets. Carcinogenesis 19: 1269-1273, 1998.
7. Jankun J, Al-Senaidy A and Skrzypczak-Jankun E: Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes (Review)? Int J Mol Med 29: 3-11, 2012.
8. Jankun J, Selman SH, Aniola J and Skrzypczak-Jankun E: Nutraceutical inhibitors of urokinase: potential applications in prostate cancer prevention and treatment. Oncol Rep 16: 341-346, 2006.
9. Stoner GD and Mukhtar H: Polyphenols as cancer chemopreventive agents. J Cell Biochem (Suppl) 22: 169-180, 1995.
10. Deng YT and Lin JK: EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest. J Agric Food Chem 59: 13318-13327, 2011.
11. Garbisa S, Biggin S, Cavallarin N, Sartor L, Benelli R and Albini A: Tumor invasion: molecular shears blunted by green tea. Nat Med 5: 1216, 1999.
12. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R and Albini A: Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 91: 822-832, 2001.
13. Jankun J, Selman SH, Swiercz R and Skrzypczak-Jankun E: Why drinking green tea could prevent cancer. Nature 387: 561, 1997.
14. Singh BN, Shankar S and Srivastava RK: Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82: 1807-1821, 2011.
15. Beltz LA, Bayer DK, Moss AL and Simet IM: Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 6: 389-406, 2006.
16. Boissier S, Ferreras M, Peyruchaud O, et al: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954, 2000.
17. Lah TT, Duran Alonso MB and Van Noorden CJ: Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther 6: 257-279, 2006.
18. Tanimura S, Kadomoto R, Tanaka T, Zhang YJ, Kouno I and Kohno M: Suppression of tumor cell invasiveness by hydrolyzable tannins (plant polyphenols) via the inhibition of matrix metalloproteinase-2/-9 activity. Biochem Biophys Res Commun 330: 1306-1313, 2005.
19. Park JW, Hong JS, Lee KS, Kim HY, Lee JJ and Lee SR: Green tea polyphenol (-)-epigallocatechin gallate reduces matrix metalloproteinase-9 activity following transient focal cerebral ischemia. J Nutr Biochem 21: 1038-1044, 2010.
20. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep 24: 747-757, 2010.
21. Sen T and Chatterjee A: Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor α5β1 in the process. Eur J Nutr 50: 465-478, 2011.
22. Chung JY, Park JO, Phyu H, Dong Z and Yang CS: Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3′-digallate. FASEB J 15: 2022-2024, 2001.
23. Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH and Jankun J: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 8: 463-470, 2001.
24. Swiercz R, Skrzypczak-Jankun E, Merrell MM, Selman SH and Jankun J: Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep 6: 523-526, 1999.
25. Miyake K, Shimada M, Nishioka M, et al: Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer. Cancer Chemother Pharmacol 64: 885-892, 2009.
26. Jiang J, Eliaz I and Sliva D: Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid: mechanism of activity. Int J Oncol 38: 1675-1682, 2011.
27. Shankar S, Ganapathy S and Srivastava RK: Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci 12: 4881-4899, 2007.
28. Selman SH and Keck RW: A comparative study of the inhibiting effects of mitomycin C and polyphenolic catechins on tumor cell implantation/growth in a rat bladder tumor model. J Urol 186: 702-706, 2011.
29. Xiao Z, McCallum TJ, Brown KM, et al: Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer 81: 638-646, 1999.
30. Trott O and Olson AJ: AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455-461, 2010.
31. Tochowicz A, Maskos K, Huber R, et al: Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol 371: 989-1006, 2007.
32. Fish PV, Barber CG, Brown DG, et al: Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem 50: 2341-2351, 2007.
33. Bikadi Z, Hazai E, Zsila F and Lockwood SF: Molecular modeling of non-covalent binding of homochiral (3S,3′S)-astaxanthin to matrix metalloproteinase-13 (MMP-13). Bioorg Med Chem 14: 5451-5458, 2006.
34. D'Hoedt D and Bertrand D: Nicotinic acetylcholine receptors: an overview on drug discovery. Expert Opin Ther Targets 13: 395-411, 2009.
35. Hetenyi C and van der Spoel D: Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett 580: 1447-1450, 2006.
36. Iorga B, Herlem D, Barre E and Guillou C: Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the 'blind docking' approach. J Mol Model 12: 366-372, 2006.
37. DeLano WL: The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA, http://www.pymol.org., 2002.
38. DeLano WL: The case for open-source software in drug discovery. Drug Discov Today 10: 213-217, 2005.
39. http://www.genecards.org/cgi-bin/carddisp.pl?gene=PLAU&rf =/home/genecards/current/website/carddisp.pl&ortholog= all# orthologs.
40. http://www.genecards.org/cgi-bin/carddisp.pl?gene=MMP9&rf= /home/genecards/current/website/carddisp.pl&ortholog=all# orthologs.
41. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J and Dumont R: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161: 1120-1123, 1999.
42. Witjes JA: Current recommendations for the management of bladder cancer. Drug therapy. Drugs 53: 404-414, 1997.
43. Wang X, Lin YW, Wang S, et al: A meta-analysis of tea consumption and the risk of bladder cancer. Urol Int 90: 10-16, 2013.
44. Wu S, Li F, Huang X, et al: The association of tea consumption with bladder cancer risk: a meta-analysis. Asia Pac J Clin Nutr 22: 128-137, 2013.
45. Lecumberri E, Dupertuis YM, Miralbell R and Pichard C: Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clinical Nutr: Mar 15, 2013 (Epub ahead of print). pii: S0261-5614(13)00086-1. doi: 10.1016/j.clnu.2013.03.008, 2013.
46. Mak JC: Potential role of green tea catechins in various disease therapies: progress and promise. Clin Exp Pharmacol Physiol 39: 265-273, 2012.
47. Shirakami Y, Shimizu M and Moriwaki H: Cancer chemoprevention with green tea catechins: from bench to bed. Curr Drug Targets 13: 1842-1857, 2012.
48. Yang CS and Wang X: Green tea and cancer prevention. Nutr Cancer 62: 931-937, 2010.
49. Kamat AM and Lamm DL: Chemoprevention of bladder cancer. Urol Clin North Am 29: 157-168, 2002.
50. Maeda-Yamamoto M, Kawahara H, Tahara N, Tsuji K, Hara Y and Isemura M: Effects of tea polyphenols on the invasion and matrix metalloproteinases activities of human fibrosarcoma HT1080 cells. J Agric Food Chem 47: 2350-2354, 1999.
51. Demeule M, Brossard M, Page M, Gingras D and Beliveau R: Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta 1478: 51-60, 2000.
52. Boehm K, Borrelli F, Ernst E, et al: Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev: CD005004, 2009.
53. Kim SJ, Jeong HJ, Lee KM, et al: Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem 18: 587-596, 2007.
54. No JH, Jo H, Kim SH, et al: Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia. Ann NY Acad Sci 1171: 100-104, 2009.
55. Racioppi M, Porreca A, Foschi N, Delicato G, Destito A and D'Addessi A: Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C. Urol Int 75: 373-375, 2005.
56. Zang Z, Xu H, Yu L, et al: Intravesical immunotoxin as adjuvant therapy to prevent the recurrence of bladder cancer. Chin Med J 113: 1002-1006, 2000.